Skip to content
value.today
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp.

TNXP
$111 Mmarket cap on Oct 20, 2026+384.1% since Jan 2024
Compare
World rank
#18,349
Revenue
$13 M
For year ending December-2025
Net income
$-124 M
-946.0% margin
SEC filing
Employees
—

Tonix Pharmaceuticals Holding Corp. in brief

Tonix Pharmaceuticals Holding Corp. is a listed company in the Biotechnology industry, based in Berkeley Heights, New Jersey, USA. Its market value was $111 M on 20 October 2026, which makes it the 18,349th largest listed company in the world and the 3,468th largest in the USA on this site. In the year to December 2025 it had sales of $13 M and a net loss of $124 M. Seth Lederman is its chief executive. Its largest product and service lines by sales in 2025 were Zembrace Symtouch (71%), Tosymra (18%) and Tonmya (11%). Its shares trade under the symbol TNXP (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Tonix Pharmaceuticals Holding Corp. timeline

4 events, 2008–2025
  1. 2008
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2011
  4. ✎
    Renamed Tonix Pharmaceuticals Holding Corp.
    Formerly Tamandare Explorations Inc..
  5. 2018
  6. •
    Legal Entity Identifier issued
    LEI 529900ACPKP9QW20GX48 registered.
  7. 2025
  8. 💰
    Record revenue of $13 million
    FY2025, the highest of the 3 years on record.

Events of Tonix Pharmaceuticals Holding Corp. from SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$59 M$118 M$177 M$235 M2020202120222023202420252026

World rank over time

▲ up 8,047 places since 2020
2020-01-01: #26437#26,43720202021-01-01: #17199#17,19920212022-01-07: #19819#19,81920222022-12-25: #29460#29,46020222023-07-30: #31241#31,24120232024-01-05: #28310#28,31020242026-03-08: #9273#9,27320262026-08-01: #15160#15,16020262026-10-14: #18174#18,17420262026-10-20: #18390#18,3902026

Rank in USA: #4,672 (Jan 2020) · #3,525 (Jan 2021) · #3,997 (Jan 2022) · #5,304 (Dec 2022) · #5,392 (Jul 2023) · #4,324 (Jan 2024) · #1,783 (Mar 2026) · #3,058 (Aug 2026) · #3,398 (Oct 2026) · #3,471 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
8.5×
Price / book
0.5×
Free cash flow yield
-92.7%
Net margin
-946.0%
Operating margin
-958.8%
Return on equity
-50.6%
Liabilities / assets
11.6%
Net debt
$-90M
Revenue growth
+29.9%
R&D / revenue
339.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-26M—FY18Fiscal year ending Dec 2019: revenue —, net income $-29M—FY19Fiscal year ending Dec 2020: revenue —, net income $-50M—FY20Fiscal year ending Dec 2021: revenue —, net income $-92M—FY21Fiscal year ending Dec 2022: revenue —, net income $-110M—FY22Fiscal year ending Dec 2023: revenue $8M, net income $-117M$8MFY23Fiscal year ending Dec 2024: revenue $10M, net income $-130M$10MFY24Fiscal year ending Dec 2025: revenue $13M, net income $-124M$13MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$13M+29.9%$-126M$-124M-946.0%
Dec 2024$10M+29.9%$-137M$-130M-1288.8%
Dec 2023$8M—$-118M$-117M-1501.4%
Dec 2022——$-112M$-110M—
Dec 2021——$-92M$-92M—
Dec 2020——$-51M$-50M—
Dec 2019——$-29M$-29M—
Dec 2018——$-26M$-26M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-100M$3M$-103M$-14.57—
Dec 2024$-61M$0M$-61M$-176.60—
Dec 2023$-102M$8M$-110M$-14720.25—
Dec 2022$-98M$48M$-146M$-20.01—
Dec 2021$-76M$35M$-111M$-8.10—
Dec 2020$-49M$9M$-57M$-0.55—
Dec 2019$-27M$0M$-27M$-19.33—
Dec 2018$-24M$0M$-24M$-259.85—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $3M, net income $-22M$3MDec ’24Three months to Mar 2025: revenue $2M, net income $-17M$2MMar ’25Three months to Jun 2025: revenue $2M, net income $-28M$2MJun ’25Three months to Sep 2025: revenue $3M, net income $-32M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $5M, net income $-47M$5MDec ’25Three months to Mar 2026: revenue $7M, net income $-40M$7MMar ’26Three months to Jun 2026: revenue $14M, net income $-41M$14MJun ’26Three months to Sep 2026: revenue $17M, net income $-53M$17MSep ’26

Latest quarter to Sep 2026: revenue $17M (+423.7% on a year earlier), net income $-53M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Tonix Pharmaceuticals Holding Corp. with the US Securities and Exchange Commission.

Annual results

Revenue
$13 M
Operating income
$-126 M
Net income
$-124 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$277 M
Total liabilities
$32 M
Total equity
$245 M

As of December-2025

Top 100 institutional investors in Tonix Pharmaceuticals Holding Corp.#

As of Sep 30, 2026
113 institutions held 10.1 M shares (about 51.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 36.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Tonix Pharmaceuticals Holding Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.1,563,129+165,088 (+11.81%)8.04%$15 MNov 13, 2026
2Point72 Asset Management, L.P.1,116,449-50,303 (-4.31%)5.75%$11 MNov 16, 2026
3Millennium Management LLC818,779-148,153 (-15.32%)4.21%$8 MNov 16, 2026
4Vanguard Capital Management LLC691,8950 (0.00%)3.56%$7 MNov 13, 2026
5AQR Capital Management LLC670,805-211,790 (-24.00%)3.45%$7 MNov 16, 2026
6Jones Hill Capital LP563,739-61,689 (-9.86%)2.90%$5 MNov 13, 2026
7Logos Global Management LP550,000New2.83%$5 MNov 16, 2026
8Geode Capital Management, LLC425,177+29,917 (+7.57%)2.19%$4 MNov 6, 2026
9Citadel Advisors LLC337,434+141,575 (+72.28%)1.74%$3 MNov 16, 2026
10State Street Corp335,083+63,709 (+23.48%)1.72%$3 MNov 12, 2026
11Essex Investment Management Co LLC292,397+127,253 (+77.06%)1.50%$3 MOct 19, 2026
12Trexquant Investment LP263,591+199,956 (+314.22%)1.36%$3 MNov 16, 2026
13FMR LLC231,852+138,301 (+147.83%)1.19%$2 MNov 10, 2026
14UBS Group AG153,026-78,656 (-33.95%)0.79%$1 MNov 10, 2026
15Northern Trust Corp128,474+8,088 (+6.72%)0.66%$1 MNov 16, 2026
16Nuveen, LLC118,761+1,314 (+1.12%)0.61%$1 MNov 10, 2026
17Vanguard Fiduciary Trust Co118,107+16,053 (+15.73%)0.61%$1 MNov 13, 2026
18Vanguard Portfolio Management LLC112,171+14,217 (+14.51%)0.58%$1 MNov 13, 2026
19Goldman Sachs Group Inc104,487+6,131 (+6.23%)0.54%$1 MNov 16, 2026
20Susquehanna Portfolio Strategies, LLC101,161+36,137 (+55.57%)0.52%$1 MNov 16, 2026
21Legato Capital Management LLC90,340+34,720 (+62.42%)0.46%$1 MNov 10, 2026
22Man Group plc80,374+61,705 (+330.52%)0.41%$1 MNov 16, 2026
23Superstring Capital Management LP74,688+11,040 (+17.35%)0.38%$1 MNov 16, 2026
24Panagora Asset Management Inc69,771+13,065 (+23.04%)0.36%$1 MNov 12, 2026
25Jacobs Levy Equity Management, Inc67,213+9,270 (+16.00%)0.35%$1 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Tonix Pharmaceuticals Holding Corp.
#InstitutionShares heldChange (shares)% heldValueFiled
26Ieq Capital, LLC61,595-30,778 (-33.32%)0.32%$1 MNov 10, 2026
27SEI Investments Co57,360+20,888 (+57.27%)0.30%$1 MNov 10, 2026
28Charles Schwab Investment Management Inc56,454+3,841 (+7.30%)0.29%$1 MNov 16, 2026
29Invesco Ltd.51,039+13,348 (+35.41%)0.26%$0 MNov 12, 2026
30Bridgeway Capital Management, LLC44,673+24,673 (+123.36%)0.23%$0 MNov 16, 2026
31Bank of New York Mellon Corp41,732-22 (-0.05%)0.21%$0 MNov 5, 2026
32Los Angeles Capital Management LLC40,216+40,140 (+52815.79%)0.21%$0 MNov 12, 2026
33D. E. Shaw & Co., Inc.35,294New0.18%$0 MNov 16, 2026
34Two Sigma Investments, LP31,153+2,341 (+8.13%)0.16%$0 MNov 16, 2026
35Jain Global LLC25,902New0.13%$0 MNov 16, 2026
36Bank Of America Corp /de/25,674-35,303 (-57.90%)0.13%$0 MNov 16, 2026
37Morgan Stanley24,782+9,541 (+62.60%)0.13%$0 MNov 13, 2026
38Alliancebernstein L.P.24,0300 (0.00%)0.12%$0 MNov 16, 2026
39Balyasny Asset Management L.P.23,819-108,772 (-82.04%)0.12%$0 MNov 16, 2026
40Squarepoint Ops LLC21,530New0.11%$0 MNov 9, 2026
41Empowered Funds, LLC19,673New0.10%$0 MNov 13, 2026
42Mariner, LLC19,393-22,377 (-53.57%)0.10%$0 MNov 12, 2026
43Price T Rowe Associates Inc /MD/19,3630 (0.00%)0.10%$0 MNov 16, 2026
44Rhumbline Advisers18,390+956 (+5.48%)0.09%$0 MNov 10, 2026
45Cerity Partners LLC18,251-12,823 (-41.27%)0.09%$0 MNov 13, 2026
46Acadian Asset Management LLC15,311New0.08%$0 MNov 9, 2026
47American Century Companies Inc15,2580 (0.00%)0.08%$0 MNov 12, 2026
48Raymond James Financial Inc15,207New0.08%$0 MNov 12, 2026
49Dimensional Fund Advisors LP14,5210 (0.00%)0.07%$0 MNov 4, 2026
50Virtu Financial LLC13,796New0.07%$0 MNov 17, 2026
51Deutsche Bank AG\13,771+1,223 (+9.75%)0.07%$0 MNov 6, 2026
52Arax Advisory Partners13,656-3,742 (-21.51%)0.07%$0 MNov 12, 2026
53Mercer Global Advisors Inc /adv13,499-10,319 (-43.32%)0.07%$0 MNov 16, 2026
54Prudential Financial Inc13,405New0.07%$0 MNov 16, 2026
55Susquehanna Fundamental Investments, LLC13,200New0.07%$0 MNov 16, 2026
56Bolton Securities Corporation13,0000 (0.00%)0.07%$0 MNov 12, 2026
57Acorn Wealth Advisors, LLC13,000New0.07%$0 MOct 19, 2026
58Wealth Enhancement Advisory Services, LLC12,613-11,066 (-46.73%)0.06%$0 MOct 13, 2026
59Savant Capital, LLC12,186New0.06%$0 MNov 6, 2026
60Axq Capital, LP12,090New0.06%$0 MNov 12, 2026
61Canada Pension Plan Investment Board11,500New0.06%$0 MNov 16, 2026
62Barclays PLC10,472+3,126 (+42.55%)0.05%$0 MNov 6, 2026
63Larson Financial Group LLC9,700-25 (-0.26%)0.05%$0 MNov 5, 2026
64MetLife Investment Management, LLC9,1190 (0.00%)0.05%$0 MNov 16, 2026
65Russell Investments Group, Ltd.8,944+1,025 (+12.94%)0.05%$0 MNov 6, 2026
66Jpmorgan Chase & Co8,775+2,664 (+43.59%)0.05%$0 MNov 12, 2026
67MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.7,832+1,141 (+17.05%)0.04%$0 MNov 16, 2026
68Vanguard Global Advisers, LLC7,323+2,594 (+54.85%)0.04%$0 MNov 13, 2026
69Wells Fargo & Company/mn6,408-9,010 (-58.44%)0.03%$0 MNov 16, 2026
70BNP Paribas Financial Markets5,948+3,976 (+201.62%)0.03%$0 MNov 12, 2026
71Police & Firemen's Retirement System of New Jersey4,9110 (0.00%)0.03%$0 MNov 9, 2026
72Tower Research Capital LLC (TRC)4,813+4,524 (+1565.40%)0.02%$0 MNov 16, 2026
73Steward Partners Investment Advisory, LLC4,000New0.02%$0 MNov 13, 2026
74Cornerstone National Bank & Trust Co3,3300 (0.00%)0.02%$0 MOct 20, 2026
75New York State Common Retirement Fund2,9000 (0.00%)0.01%$0 MNov 17, 2026
76Global Retirement Partners, LLC2,893New0.01%$0 MNov 10, 2026
77UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,173+2,032 (+1441.13%)0.01%$0 MNov 16, 2026
78Nisa Investment Advisors, LLC2,125-2,817 (-57.00%)0.01%$0 MOct 20, 2026
79Legal & General Group Plc1,4700 (0.00%)0.01%$0 MNov 16, 2026
80Ameritas Investment Partners, Inc.1,459+686 (+88.75%)0.01%$0 MNov 13, 2026
81Strs Ohio1,100New0.01%$0 MOct 30, 2026
82Rockefeller Capital Management L.P.870+500 (+135.14%)0.00%$0 MNov 13, 2026
83Royal Bank Of Canada851-10 (-1.16%)0.00%$0 MNov 16, 2026
84Allworth Financial LP825-228 (-21.65%)0.00%$0 MNov 17, 2026
85Citigroup Inc800-5,927 (-88.11%)0.00%$0 MNov 4, 2026
86IFP Advisors, Inc796-653 (-45.07%)0.00%$0 MOct 16, 2026
87PNC Financial Services Group, Inc.741+573 (+341.07%)0.00%$0 MNov 6, 2026
88Essential Partners LLC693-409 (-37.11%)0.00%$0 MOct 14, 2026
89EverSource Wealth Advisors, LLC623-550 (-46.89%)0.00%$0 MNov 4, 2026
90Osaic Holdings, Inc.620-1,547 (-71.39%)0.00%$0 MNov 12, 2026
91Farther Finance Advisors, LLC574+272 (+90.07%)0.00%$0 MOct 8, 2026
92Gen-Wealth Partners Inc5330 (0.00%)0.00%$0 MNov 4, 2026
93Optiver Holding B.V.518New0.00%$0 MNov 16, 2026
94SJS Investment Consulting Inc.484-9,720 (-95.26%)0.00%$0 MOct 26, 2026
95Sterling Capital Management LLC319+25 (+8.50%)0.00%$0 MOct 22, 2026
96GAMMA Investing LLC252-36 (-12.50%)0.00%$0 MOct 8, 2026
97California State Teachers Retirement System1910 (0.00%)0.00%$0 MNov 13, 2026
98MassMutual Private Wealth & Trust, FSB1600 (0.00%)0.00%$0 MOct 5, 2026
99Rothschild Investment LLC146-153 (-51.17%)0.00%$0 MNov 10, 2026
100Root Financial Partners, LLC137New0.00%$0 MOct 21, 2026

All 113 institutional investors, with who bought and sold →

Mutual funds holding Tonix Pharmaceuticals Holding Corp.#

87 funds hold shares worth $28 M (about 11.7% of the company). Since their previous reports 59 added shares and 6 sold, buying $8 M net.
Mutual funds holding Tonix Pharmaceuticals Holding Corp.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.488,108$6 M2.5%<0.01%+36%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors389,931$5 M2.0%<0.01%+18%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.187,414$2 M0.96%<0.01%+28%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors145,820$2 M0.75%0.01%+25%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC158,829$2 M0.82%<0.01%+18%Jul 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC78,342$1 M0.40%0.02%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.69,338$1 M0.36%<0.01%+21%May 31, 2026
🇺🇸 1290 Essex Small Cap Growth FundEquitable Investment Management, LLC73,840$1 M0.38%0.64%newJul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC54,920$1 M0.28%<0.01%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors49,085$1 M0.25%0.04%+43%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC35,565$0 M0.18%<0.01%−43%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC29,354$0 M0.15%<0.01%+49%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.36,301$0 M0.19%<0.01%+22%Jul 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC31,079$0 M0.16%<0.01%−55%Jul 31, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC22,648$0 M0.12%0.08%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC21,661$0 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC20,358$0 M0.10%0.01%+21%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC20,000$0 M0.10%0.17%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC19,343$0 M0.10%<0.01%+14%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors17,997$0 M0.09%<0.01%+3.1%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC17,892$0 M0.09%<0.01%+46%Jun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC21,611$0 M0.11%<0.01%+100%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC19,503$0 M0.10%<0.01%+38%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC13,190$0 M0.07%<0.01%+71%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.16,263$0 M0.08%<0.01%no changeJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust12,850$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC11,508$0 M0.06%0.02%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC10,840$0 M0.06%<0.01%+102%Jun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors10,495$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.10,431$0 M0.05%0.01%+23%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.8,566$0 M0.04%<0.01%+106%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.8,521$0 M0.04%<0.01%+239%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.7,807$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.7,701$0 M0.04%<0.01%+7.8%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation7,600$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.7,400$0 M0.04%<0.01%+37%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC7,600$0 M0.04%<0.01%+15%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC9,314$0 M0.05%<0.01%+41%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC6,590$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC6,334$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company5,930$0 M0.03%<0.01%+40%May 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC6,926$0 M0.04%<0.01%+16%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP6,874$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC4,995$0 M0.03%<0.01%+12%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC6,070$0 M0.03%<0.01%+37%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.4,700$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP4,993$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS3,624$0 M0.02%<0.01%+47%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC3,589$0 M0.02%<0.01%+48%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,317$0 M0.02%0.02%+37%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC3,255$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC3,016$0 M0.02%<0.01%+22%Jun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC2,699$0 M0.01%0.02%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.2,356$0 M0.01%<0.01%+22%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.2,199$0 M0.01%<0.01%+43%Jun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC2,106$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,053$0 M0.01%<0.01%+41%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC2,610$0 M0.01%<0.01%+30%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,557$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP1,970$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,838$0 M<0.01%<0.01%+26%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,708$0 M<0.01%<0.01%+76%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.1,270$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,163$0 M<0.01%<0.01%+57%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,442$0 M<0.01%<0.01%+807%Jul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,093$0 M<0.01%<0.01%+24%Jun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC1,076$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION1,100$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC974$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,193$0 M<0.01%<0.01%+137%Jul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC927$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC899$0 M<0.01%<0.01%+73%Jun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,061$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC1,037$0 M<0.01%<0.01%−13%Jul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management773$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC726$0 M<0.01%<0.01%+169%Jun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC684$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC639$0 M<0.01%<0.01%+27%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC500$0 M<0.01%<0.01%−31%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC506$0 M<0.01%<0.01%−29%May 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC315$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.300$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC244$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC215$0 M<0.01%<0.01%+13%Jun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.108$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Wilshire 5000 Index FundWilshire Advisors LLC76$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC77$0 M<0.01%<0.01%+6.9%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 87 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Tonix Pharmaceuticals Holding Corp.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$479 K
8 purchases, 4 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$479 K
open market only
Insiders on file
21
since
$286 K$0May 2025: bought $86 K (1 trades), sold $0 (0 trades)May 25Aug 2025: bought $24 K (2 trades), sold $0 (0 trades)AugMar 2026: bought $286 K (2 trades), sold $0 (0 trades)MarJun 2026: bought $132 K (3 trades), sold $0 (0 trades)JunAug 2026: bought $40 K (2 trades), sold $0 (0 trades)AugNov 2026: bought $20 K (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Tonix Pharmaceuticals Holding Corp.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Seth LedermanChief Executive Officer, DirectorBuy+5,000$4.055$20 K16,005Form 4
filed Seth LedermanChief Executive Officer, DirectorBuyindirect+2,000$13.79$28 K11,005Form 4
filed Richard H. BaggerDirectorBuy+1,000$12.60$13 K1,000Form 4
filed Bradley SaengerChief Financial OfficerOther+1,453$10.91$16 K2,154Form 4
filed Carolyn E. TaylorDirectorBuy+1,415$10.55$15 K1,833Form 4
filed Seth LedermanChief Executive Officer, DirectorBuy+5,000$11.79$59 K9,005Form 4
filed Richard Newcomb StillwellDirectorBuy+5,000$11.65$58 K5,000Form 4
filed Seth LedermanChief Executive Officer, DirectorBuyindirect+5,000$12.62$63 K20,001Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Tonix Pharmaceuticals Holding Corp.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.3 M
25.9% of shares · 4.14 days to cover
Buybacks, Q4 2025
$7.8M
Q4 2025
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split ; 1-for-10 reverse split

Tonix Pharmaceuticals Holding Corp. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2025Q4 2025$7.8M
Q3 2025Q3 2025$0M
Q2 2025Q2 2025$2.9M
Q1 2025Q1 2025$3M
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q2 2023Q2 2023$0M
Q1 2023Q1 2023$14M

Trading halts

  • 2025-08-18 13:33 UTC, code LUDP, resumed 13:38 UTC
  • 2025-08-15 17:03 UTC, code T3, resumed 20:15 UTC
  • 2025-02-05 00:50 UTC, code T3, resumed 14:00 UTC
  • 2024-12-17 14:47 UTC, code LUDP, resumed 14:52 UTC
  • 2024-12-17 14:40 UTC, code LUDP, resumed 14:45 UTC

Fails to deliver

  • : 27,371 shares at $5.73
  • : 7 shares at $6.04
  • : 24,282 shares at $6.13
  • : 2,201 shares at $7.55
  • : 8,285 shares at $9.23

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Tonix Pharmaceuticals Holding Corp. scorecard#

Passes 5 of the 17 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median8.5×Price to sales 8.5× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-92.7%Free cash flow is -92.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 3
    • ✓Revenue grew in the newest year29.9%Revenue up 29.9% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-14.57 vs -176.60Diluted EPS -14.57 in fiscal 2025 against -176.60 the year before (report's currency).
    • ✗Net income higher than five years earlier-$124 M-$124 M in fiscal 2025 against -$50 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 4
    • ✗Profitable in the newest year-$124 MNet income -$124 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-958.8%-958.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-64.5%-64.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities7.4×Current ratio 7.42 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-2.82Z-score -2.82 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 2
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • ✓Dividends and buybacks above 3% of the market value12.4%Dividends and buybacks were 12.4% of the market value.
    • ✗Free cash flow covers dividends and buybacks-$103 MFree cash flow -$103 M against $14 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Tonix Pharmaceuticals Holding Corp.'s statements, beside the median of Biotechnology.

Tonix Pharmaceuticals Holding Corp.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-958.8%-60.5%
Net margin-946.0%-68.9%
Return on equity-64.5%-61.0%
Revenue growth29.9%15.8%
Free cash flow margin-787.3%-61.5%

4of 8on the Piotroski tests of financial strength

  • Net loss of $124 million, the 16th loss-making year in a row.
  • Free cash flow was negative: -$103 million.
  • Receivables grew 70% while revenue grew 30%: customers are paying later, or sales were booked ahead of cash.

Tonix Pharmaceuticals Holding Corp.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Tonix Pharmaceuticals Holding Corp.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue13107.8———————
Cost of revenue6.67.84.7———————
Research and development44408782693618181329
Selling, general and administrative88403530——————
General and administrative———302314118.87.910
Total costs and expenses139147126112925129262139
Operating income−126−137−118−112−92−51−29−26−21−39
Interest and finance income4.10.01.71.90.00.00.20.20.20.1
Interest expense and finance costs0.11.2————————
Provision for credit losses0.0—————————
Other non-operating income (expense)−3.3−0.9r1.7———————
Income before tax————————−21−39
Net income attributable to shareholders−124−130−117−110−92−50−29−26−21−39
Earnings per share, basic-14.57-176.60-14,720.25r-20.01r-8.10r-0.55-19.33-259.85r-31.69r-15.41
Earnings per share, diluted-14.57-176.60-14,720.25r-20.01r-8.10r-0.55-19.33-259.85r-31.69r-15.41
Shares, weighted average (basic)8.50.70.0r5.8r11—————
Shares, weighted average (diluted)8.50.70.0r5.8r11r951.60.1r0.7r2.5
Balance sheet
Cash and cash equivalents20899251201797711252519
Receivables6.33.7————————
Inventory—8.414———————
Other current assets9.08.12.21110112.71.00.91.0
Current assets229119481311898814262627
Property, plant and equipment44429494518.60.00.00.10.2
Right-of-use (leased) assets1.50.60.80.70.91.30.4———
Goodwill——1.0———————
Other intangible assets0.10.19.70.10.10.10.10.10.10.1
Total assets2771631542262419815262728
Accounts payable8.14.53.88.1134.63.11.41.30.9
Debt due within a year—2.82.4———————
Current liabilities31181918229.85.12.72.12.1
Long-term debt—4.76.6———————
Lease liabilities (non-current)1.20.40.60.30.50.70.0———
Total liabilities3223491922115.12.72.12.1
Retained earnings−855−731−601−470−360−268−217−188−162−141
Shareholders' equity245140106207219889.4242525
Total liabilities and equity2771631542262419815262728
Shares outstanding134.40.0r12r16r2068.50.3r0.8r3.9r
Cash-flow statement
Depreciation and amortization1.93.44.31.30.10.00.00.10.10.2
Share-based compensation6.04.89.3117.92.91.51.61.83.3
Cash from operating activities−100−61−102−98−76−49−27−24−19−37r
Capital expenditure−3.4−0.1−7.9−48−35−8.6−0.0−0.0−0.0−0.1
Cash from investing activities−4.5−0.1−29−48−35−8.6−0.0−0.07.217r
Debt repaid−9.7−2.4————————
Shares issued23814019942121095.8r131920
Shares bought back−14—−14———————
Cash from financing activities215135378821212313241920
Exchange-rate effect on cash−0.00.0−0.1−0.1−0.0−0.0−0.0−0.0——
Change in cash11074−95−5810266−14−0.56.6−0.3r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Tonix Pharmaceuticals Holding Corp. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Zembrace Symtouch$9 M71%
  • Tosymra$2 M18%
  • Tonmya$1 M11%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Tonix Pharmaceuticals Holding Corp. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 7 subsidiaries on file.

Tonix Pharmaceuticals Holding Corp.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters2 offices5 subsidiaries—
🇮🇪 Ireland2 subsidiaries—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Tonix Pharmaceuticals Holding Corp.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.9 M
Seth Lederman
Other top executives, average
$1.2 M
the CEO earned 2.4× this
$100 invested is now
$0
Tonix Pharmaceuticals Holding Corp.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Seth Lederman$2.9 M$4.6 M$1.2 M$0
2024Seth Lederman$1.8 M$1.1 M$887 K$0
2023Seth Lederman$2.1 M$647 K$929 K$1

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Tonix Pharmaceuticals Holding Corp.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 3 · Material agreement 2 · Shareholder vote 1 · Results announced 7

Tonix Pharmaceuticals Holding Corp.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Tonix Pharmaceuticals Holding Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2012$3 MNo. 2$2 to $10 million26equity, optionsSEC
Jan 2012$4 MNo. 1$2 to $10 million81equity, optionsSEC
Oct 2011$2 MIssued in a merger or acquisitionUnder $2 million16equity, debt, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Tonix Pharmaceuticals Holding Corp.#

$580 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, pharmacy and defense.

Lobbying, 2025
$580 K
#557 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
6
in 2025
2026 so far
$520 K
  • Health Issues13 reports
  • Pharmacy8 reports
  • Defense5 reports
  • Disaster Planning/Emergencies4 reports

Lobbying firms hired in 2025

Burrell International Group LLC $160 K · VALCOUR LLC $120 K · Strategic Marketing Innovations $80 K · Broydrick & Associates $80 K · FOLEY HOAG LLP $80 K · Cardinal Point Partners $60 K

Tonix Pharmaceuticals Holding Corp.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$520 K—17
2025$580 K—25
2024$450 K—16
2023$430 K—16
2022$250 K—14
2021$140 K—12
2020$140 K—13
2019$260 K—15
2018$120 K—14

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Tonix Pharmaceuticals”, “Tonix Pharmaceuticals, Inc.” and “Tonix Pharmaceuticals Holding Corp.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Tonix Pharmaceuticals Holding Corp.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $125 K a year.

Certified, FY2025
1
#1,991 among companies on value.today
Worker positions
1
Median wage offered
$125 K
a year, full-time
Applications filed
1
Tonix Pharmaceuticals Holding Corp.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Manager, Quality Control, Product Testing and ComplianceQuality Control Systems Managers1$125 K

Where: Dracut, MA 1

Tonix Pharmaceuticals Holding Corp.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$125 K1
FY202411$125 K1
FY202211$111 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Tonix Pharmaceuticals Inc.

Layoffs at Tonix Pharmaceuticals Holding Corp.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
23
2024–2024
Latest
23 people
2024-05-21
Tonix Pharmaceuticals Holding Corp.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024····23·······23
Tonix Pharmaceuticals Holding Corp.: latest layoffs
AnnouncedPeopleKindWhereSource
23 peopleRestructuring planSEC 8-K“(the “Company”) plans to reduce its workforce by 23 full-time employees and decommission its Advanced Development Center (“ADC”) in Massachusetts by June 7, 2024, to align the Comp…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Tonix Pharmaceuticals Holding Corp. compares in Biotechnology

  • Market cap$111 M · higher than 38% of 726
  • Revenue$13 M · higher than 46% of 647
  • Net margin-946.0% · higher than 0% of 408
  • Revenue growth29.9% · higher than 66% of 438
  • Price / sales8.5× · lower than 47% of 339
  • Price / book0.5× · lower than 93% of 534
  • FCF yield-92.7% · higher than 11% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Tonix Pharmaceuticals Holding Corp.🇺🇸$111 M—-946.0%+29.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 20, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Tonix Pharmaceuticals Holding Corp.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Tonix Pharmaceuticals Holding Corp.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Tonix Pharmaceuticals Holding Corp.? Suggest a correction